Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CD69 | Q07108 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9796074 | 1.00 | CA9 (0.39) | CA9CA12CA2CA1TSHR | |
| SCHEMBL15975969 | 1.00 | CA9 (0.39) | CA9CA12CA2CA1TSHR | |
| SCHEMBL9796069 | 1.00 | CA9 (0.39) | CA9CA12CA2CA1TSHR | |
| SCHEMBL29904557 | 1.00 | CA9 (0.39) | CA9CA12CA2CA1TSHR | |
| SCHEMBL1258412 | 0.88 | CA9 (0.42) | CA9CA12CA2CA1TSHR | |
| SCHEMBL17285153 | 0.88 | CA9 (0.39) | CA9CA12CA2CA1TSHR | |
| SCHEMBL13804723 | 0.86 | CA9 (0.44) | CA9CA12CA2CA1TSHR | |
| SCHEMBL34470432 | 0.84 | CA9 (0.39) | CA9CA12CA2CA1TSHR | |
| SCHEMBL17285152 | 0.84 | CA9 (0.39) | CA9CA12CA2CA1TSHR | |
| SCHEMBL1259563 | 0.84 | CA9 (0.42) | CA9CA12CA2CA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087718-A1 | A MULTIVALENT SHIGELLA VACCINE AND METHODS OF MAKING AND USING THEREOF | INSTITUT PASTEUR (FR) | 2026-04-30 | — | — | WO | disclosed |
| US-12473379-B2 | Method for obtaining purified bacterial polysaccharides | SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) | 2025-11-18 | — | — | US | disclosed |
| US-12214029-B2 | Polysaccharide and uses thereof | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2025-02-04 | — | — | US | disclosed |
| EP-3110441-B1 | NOVEL POLYSACCHARIDE AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-04-03 | — | — | EP | disclosed |
| US-20230364214-A1 | Novel Polysaccharide and Uses Thereof | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2023-11-16 | — | — | US | disclosed |
| US-11738076-B2 | Polysaccharide and uses thereof | GLAXOSMITHKLINE BIOLOGICALS S.A. | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12214029-B2 | Polysaccharide and uses thereof | GALE, OSTC, ENGASE | CA9 1048/4885CA12 1716/4885CA2 3385/4885 |
| US-11738076-B2 | Polysaccharide and uses thereof | GALE, OSTC, ENGASE | CA9 1048/4885CA12 1716/4885CA2 3385/4885 |
| US-20230364214-A1 | Novel Polysaccharide and Uses Thereof | GALE, OSTC, ENGASE | CA9 1434/4885CA12 1945/4885CA2 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.